Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Hypoglycemia peptide trials
10 selected ClinicalTrials.gov records carrying the official condition label Hypoglycemia. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
10 selected records.
2 profiles.
2018–2025 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 32 selected PubMed records and 2 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Hypoglycemia unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT03216226
PeptideScanner retained ClinicalTrials.gov record NCT03216226 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-05-04, and PeptideScanner's reviewed identity mapping was dasiglucagon.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- May 4, 2021
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT03378635
PeptideScanner retained ClinicalTrials.gov record NCT03378635 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-10, and PeptideScanner's reviewed identity mapping was dasiglucagon.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- June 10, 2021
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT03667053
PeptideScanner retained ClinicalTrials.gov record NCT03667053 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-06-30, and PeptideScanner's reviewed identity mapping was dasiglucagon.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- June 30, 2021
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Dasiglucagon · 2025-07-20
ClinicalTrials.gov record NCT05378672
Completed at the retained observation.
Open attributed record →Dasiglucagon · 2023-02-21
ClinicalTrials.gov record NCT03895697
Completed at the retained observation.
Open attributed record →Dasiglucagon · 2022-09-07
ClinicalTrials.gov record NCT04764968
Completed at the retained observation.
Open attributed record →Dasiglucagon · 2021-06-30
ClinicalTrials.gov record NCT03667053
Completed at the retained observation.
Open attributed record →Dasiglucagon · 2021-06-10
ClinicalTrials.gov record NCT03378635
Completed at the retained observation.
Open attributed record →Dasiglucagon · 2021-05-19
ClinicalTrials.gov record NCT03688711
Completed at the retained observation.
Open attributed record →Dasiglucagon · 2021-05-04
ClinicalTrials.gov record NCT03216226
Completed at the retained observation.
Open attributed record →Dasiglucagon · 2021-03-23
ClinicalTrials.gov record NCT03735225
Completed at the retained observation.
Open attributed record →Dasiglucagon · 2021-02-09
ClinicalTrials.gov record NCT04449692
Completed at the retained observation.
Open attributed record →Pasireotide · 2018-03-07
ClinicalTrials.gov record NCT02527993
Completed at the retained observation.
Open attributed record →